LIPO
Lipella Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Year over year
Reported trailing growth
- Revenue
- -61.4%
- EBITDA
- -23.9%
- EBIT
- -24.1%
- EPS
- +40.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +108.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +27.4%
- EBITDA
- -8.8%
- EBIT
- -7.0%
- Net income
- -8.6%
- EPS
- +22.2%
- Free cash flow
- -24.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025